AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32897344
Drug: Out-of-hospital tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group)
Trial: 32897344
Drug: Out-of-hospital tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group)
Trial: 32323192
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg once daily (OD) or 15 mg OD if creatinine clearance was 30-49 mL/min
Trial: 32323192
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg and 20 mg OD dosages
Trial: 35112328
Drug: LY01008 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY01008 (3 mg/kg)
Trial: 33397855
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of triamcinolone acetonide 10mg/ml in 1ml with injection hyaluronidase 1500IU in 2ml with injection 2% lidocaine 7ml, administered every 15 days for 3 months (Group A)
Trial: 33397855
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of triamcinolone acetonide 10mg/ml in 1ml with injection hyaluronidase 1500IU in 2ml with injection 2% lidocaine 7ml plus oral colchicine 0.5mg twice daily for 3 months (Group B)
Trial: 32724076
Drug: Sitagliptin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin therapy for 12 months
Trial: 35935797
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs) in group B
Trial: 35935797
Drug: Flupentixol and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol and melitracen (FM) + acid-suppressive therapy (AST) in group B
Trial: 35935797
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs) in group E
Trial: 35935797
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonists (H2RAs) in group D
Trial: 35935797
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonists (H2RAs) in group A
Trial: 35935797
Drug: Acid-suppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-suppressive therapy (AST) in group C
Trial: 35722182
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg daily for 12 weeks
Trial: 34511288
Drug: Manual control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual control of oxygen titration
Trial: 34077887
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g EPA + 1.0 g DHA daily (n = 14)
Trial: 34077887
Drug: Mineral oil
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil daily (n = 18)
Trial: 33649058
Drug: Methoxyflurane administered
RxNorm normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxyflurane administered by inhalation
Trial: 33649058
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (Methoxyflurane and Morphine)
Trial: 32195952
Drug: Massage chair
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage chair therapy
Trial: 616631332
Drug: Actual lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual lithium plasma concentrations in treatment arm
Trial: 34536349
Drug: BBIBP-CorV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBIBP-CorV vaccine (2 ?g, 4 ?g, or 8 ?g)
Trial: 32899074
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of intravenous dexamethasone
Trial: 32899074
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of intravenous dexamethasone
Trial: 32899074
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of intravenous dexamethasone
Trial: 36109038
Drug: MBEC-guided antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBEC-guided antibiotic regimen
Trial: 32667729
Drug: Diuretic monotherapy
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic monotherapy
Trial: 35954320
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (treatment group)
Trial: 35954320
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (treatment group)
Trial: 33210509
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of somatostatin analogues and glucocorticoids in high risk group (25 patients)
Trial: 33647900
Drug: Serotonin (5-HT)
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin (5-HT) agonistic drugs
Trial: 33647900
Drug: Noradrenaline (NA)
RxNorm normalized name: noradrenaline hydrochloride
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Noradrenaline (NA) agonistic drugs
Trial: 33647900
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (DA) agonistic drugs
Trial: 32928167
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in addition to a diet and lifestyle intervention
Trial: 36149885
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2.5 mg of letrozole and 50 mg of clomiphene citrate (CC)
Trial: 36149885
Drug: Letrozole alone
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole alone (2.5 mg)
Trial: 34049171
Drug: Sulfurous-arsenical-ferruginous thermal
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfurous-arsenical-ferruginous thermal water inhalation (hot humid air and aerosol)
Trial: 34049171
Drug: Combined inhalation
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined inhalation and nasal irrigation of sulfurous-arsenical-ferruginous thermal water
Trial: 34119901
Drug: Autologous mesenchymal
RxNorm normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous mesenchymal stem cell therapy (MSC)
Trial: 34119901
Drug: Second course
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second course of MSC therapy
Trial: 34119901
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with AEDs
Trial: 33406269
Drug: Benzoate (250-1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoate (250-1500 mg/d)
Trial: 33567390
Drug: Psychological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatments for BED
Trial: 32438245
Drug: VAC +
RxNorm normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC + ITM (MLV-vaccine and ITM - Multimin®90 subcutaneously)
Trial: 32438245
Drug: VAC +
RxNorm normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC + SAL (MLV-vaccine and saline)
Trial: 33092805
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive intraoperative goal-directed therapy (GDT)
Trial: 35709823
Drug: Short-term anti-TNF
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term anti-TNF therapy with surgical closure
Trial: 32593253
Drug: Inactive vitamin
RxNorm normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive vitamin D treatment maintaining levels >34.3 ng/ml for 12 months
Trial: 32593253
Drug: Inactive vitamin
RxNorm normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive vitamin D treatment
Trial: 32593253
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment according to recommendations of the Russian Association of Endocrinologists
Trial: 32310005
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (performed at least twice within 6 weeks)
Trial: 32294561
Drug: IncobotulinumtoxinA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA treatment
Trial: 36434687
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT) for 20 min per session, 6 sessions total, once every two days.
Trial: 36180142
Drug: Pilates method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates method (PM) protocol, 16 sessions, twice a week (n=33)
Trial: 33737427
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care treatment without Pozzi tenaculum forceps during IUI
Trial: 33737427
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care treatment with Pozzi tenaculum forceps during IUI
Trial: 35218680
Drug: Intralesional platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional platelet-rich plasma (PRP) injections
Trial: 35218680
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide (TA) injections
Trial: 32715653
Drug: Pharmacist-managed dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-managed dosing algorithm for darbepoetin alfa (DA) and iron sucrose
Trial: 34403548
Drug: 4 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 µg/kg oral clonidine
Trial: 34403548
Drug: 2 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 µg/kg intranasal dexmedetomidine
Trial: 32228512
Drug: gemcitabine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine + nab-paclitaxel (1000 mg/m2 gemcitabine + 125 mg/m2 nab-paclitaxel)
Trial: 32228512
Drug: gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine alone (1000 mg/m2)
Trial: 38279662
Drug: MDMA 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 1.5 mg/kg
Trial: 35155865
Drug: Steroid avoidance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid avoidance protocol (tacrolimus/MMF/antithymocyte globulin [ATG] induction)
Trial: 35155865
Drug: Steroid maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid maintenance protocol (tacrolimus/MMF/prednisolone/basiliximab-induction)
Trial: 32535191
Drug: Deep learning
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep learning algorithm for automated grading of CD ulcers on capsule endoscopy images
Trial: 32535191
Drug: Consensus reading
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consensus reading by 3 capsule readers
Trial: 39529175
Drug: Sobriety Treatment
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (SOBRIETE) - BROWN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sobriety Treatment and Recovery Teams (START)
Trial: 34236624
Drug: Various therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various therapies (pharmacologic, electromagnetic, mechanical, sensory, regenerative)
Trial: 34236624
Drug: Precision medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision medicine approach
Trial: 35347164
Drug: Whole grain
RxNorm normalized name: Whole grain barley
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole grain rye/rye bran (485 g daily for 6 weeks)
Trial: 35347164
Drug: Refined wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined wheat (fiber supplemented, 485 g daily for 6 weeks)
Trial: 33607357
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg/day for 8 weeks)
Trial: 33395586
Drug: Rosa damascene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosa damascene essence 40% in distilled water inhalation for three consecutive nights from 22:00 to 06:00
Trial: 33395586
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water inhalation as placebo for three consecutive nights from 22:00 to 06:00
Trial: 35606864
Drug: Rosa canina
RxNorm normalized name: ROSA CANINA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosa canina L. syrup + methylphenidate (MP)
Trial: 35606864
Drug: Polyherbal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyherbal formulation (PHF) syrup + methylphenidate (MP)
Trial: 34921679
Drug: Test cream
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test cream containing ceramides, triglycerides, and cholesterol in a multivesicular emulsion
Trial: 34921679
Drug: Test cream
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test cream
Trial: 34921679
Drug: Reference emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference emollient cream
Trial: 35022320
Drug: HCQ 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ 600 mg po bid with D+T (dabrafenib 150 mg bid and trametinib 2 mg qd)
Trial: 35853600
Drug: Performance feedback
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Performance feedback intervention (introductory training module, weekly electronic 'Quick Tips', and 3 individualized performance feedback reports)
Trial: 32860991
Drug: Sprifermin (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprifermin (highest dose)
Trial: 36056419
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg body weight) in addition to the standard of care
Trial: 33871742
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication management
Trial: 35775704
Drug: Daylight photodynamic
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daylight photodynamic therapy (dl‐PDT)
Trial: 34479508
Drug: Reconsolidation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconsolidation Therapy (RT)
Trial: 32925713
Drug: Yangyin Shuxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangyin Shuxin Decoction combined with standard treatment
Trial: 33413555
Drug: C‐Mill training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐Mill training (10 sessions, 1 hour each, twice per week for 5 weeks)
Trial: 34610049
Drug: Screened for
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screened for AF using a continuous-recording ECG patch worn for two weeks and 2 occasions, 3 months apart.
Trial: 34836902
Drug: Usual occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual occupational therapy
Trial: 33781780
Drug: Continuous chest
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chest wall vibration with concurrent aerobic training
Trial: 34843312
Drug: Internet-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based treatment (IG)
Trial: 33580603
Drug: KRP-116D (50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRP-116D (50% dimethyl sulfoxide solution)
Trial: 33513485
Drug: CYP2D6 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2D6 genotype and functional status treatment
Trial: 33513485
Drug: Standard psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychotropic therapy
Trial: 34113353
Drug: estradiol (E2)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol (E2) patch
Trial: 34113353
Drug: transdermal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal placebo
Trial: 35614185
Drug: Chitin-glucan (CG)
RxNorm normalized name: Chitin
DrugBank: Chitin (DB15142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitin-glucan (CG) supplementation (4.5 g daily)
Trial: 34089219
Drug: VAIA III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAIA III plus optional maintenance therapy (MT) in CWS-2002P
Trial: 34522175
Drug: Short-axis hydrodissection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-axis hydrodissection (5 mL normal saline per session)
Trial: 34522175
Drug: Long-axis hydrodissection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-axis hydrodissection (5 mL normal saline per session)
Trial: 36457653
Drug: Citrus aurantium
RxNorm normalized name: Citrus aurantium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus aurantium essential oil (2 drops, twice a day, for four consecutive days a week, for four weeks)
Trial: 32791810
Drug: Cipterbin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipterbin (4 mg/kg loading dose and 2 mg/kg maintenance dose each week, IV) combined with vinorelbine (25 mg/m(2) on days 1,8 and 15 of each 28 days, IV)
Trial: 32791810
Drug: Vinorelbine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (25 mg/m(2) on days 1,8 and 15 of each 28 days, IV)
Trial: 36222438
Drug: ELOM-080 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELOM-080 (4 × 1 capsule per day)
Trial: 35411076
Drug: AAV8‐VRC07 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV8‐VRC07 (5 × 10^10, 5 × 10^11, and 2.5 × 10^12 vector genomes per kilogram by intramuscular injection)
Trial: 32673048
Drug: Alcohol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (target blood alcohol concentration of .08 g%)
Trial: 34668982
Drug: Carfilzomib (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (36 mg/m2) administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle
Trial: 33733720
Drug: Perineural corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural corticosteroid injection (Methylprednisolone acetate 40 mg and 1 mL of 1% trimecaine hydrochloride injected next to the median nerve)
Trial: 33733720
Drug: Peritendinous corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritendinous corticosteroid injection (Methylprednisolone acetate 40 mg and 1 mL of 1% trimecaine hydrochloride injected among flexor tendons away from the nerve)
Trial: 32910476
Drug: Interaction between
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interaction between treatment arms
Trial: 35260570
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a RAC1/RAC3 dual-target inhibitor and cetuximab
Trial: 33305109
Drug: Etelcalcetide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide + oral calcium preparation (group E+Ca)
Trial: 35367787
Drug: Metronomic adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic adjuvant chemotherapy (MAC) consisting of weekly oral methotrexate (15 mg/m²) and celecoxib (200 mg orally twice daily) for 6 months
Trial: 32222134
Drug: Vericiguat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat (10 mg once daily)